Researchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.
|Slideshows|September 19, 2019
- Drug Topics September 2019
- Volume 163
- Issue 9
Antibiotic Counseling Pearls for the Community Setting
Author(s)Jennifer Gershman, PharmD, CPh
Advertisement
Swipe through the following images for antibiotic counseling tips for patients, from Antimicrobial Stweardship: Protecting Global Health.
Articles in this issue
almost 7 years ago
Biosimilars: Some Call for ‘Cautious Optimism’almost 7 years ago
Generics of Older Drugs Could Have Saved Medicare Billions, Study Saysalmost 7 years ago
Biosimilars Need Access and Cost Examinationsalmost 7 years ago
The Latest Autoimmune Disease Treatment Advancesalmost 7 years ago
Unique Offerings Increasing Revenuealmost 7 years ago
The Growing Problem of Pharmacy Desertsalmost 7 years ago
What is a Pharmacy Desert?almost 7 years ago
Patient Services are Crucial to the Economics of Pharmacyabout 7 years ago
New Video Marketing Toolsabout 7 years ago
Antimicrobial Stewardship: Protecting Global HealthAdvertisement
Related to this article
Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Expert Discusses Flu and COVID-19 Vaccine Guidance
3
Oveporexton Met Primary, Key Secondary End Points in Phase 3 Studies
4
Generic Drug Costs Burdening Patients as Much as Brand Name Options
5